Do analysts prefer MOR or COLL?

Collegium Pharmaceutical has a consensus target price of $48.50, suggesting a potential upside of 113.00%. Given Collegium Pharmaceutical's stronger consensus rating and higher possible upside, analysts clearly believe Collegium Pharmaceutical is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Collegium Pharmaceutical 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.50

Does the media refer more to MBX or COLL?

In the previous week, Collegium Pharmaceutical had 1 more articles in the media than MBX Biosciences. MarketBeat recorded 4 mentions for Collegium Pharmaceutical and 3 mentions for MBX Biosciences. MBX Biosciences' average media sentiment score of 0.45 beat Collegium Pharmaceutical's score of -0.26 indicating that MBX Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Collegium Pharmaceutical 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, COLL or RGC?

Collegium Pharmaceutical has higher revenue and earnings than Regencell Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Collegium Pharmaceutical $780.57M 0.95 $62.87M $1.24 18.36 Regencell Bioscience N/A N/A -$3.58M N/A N/A

Does the media prefer GPCR or COLL?

In the previous week, Collegium Pharmaceutical had 1 more articles in the media than Structure Therapeutics. MarketBeat recorded 4 mentions for Collegium Pharmaceutical and 3 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 0.51 beat Collegium Pharmaceutical's score of -0.26 indicating that Structure Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Collegium Pharmaceutical 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Collegium Pharmaceutical (COLL) Competitors

$22.77 +0.39 (+1.74%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$22.80 +0.03 (+0.13%)

As of 09/18/2026 07:30 PM Eastern

Compare

COLL vs. MOR, MBX, RGC, ATAI, and GPCR

Should you buy Collegium Pharmaceutical stock or one of its competitors? Collegium Pharmaceutical's main competitors and comparable companies include MorphoSys (MOR), MBX Biosciences (MBX), Regencell Bioscience (RGC), Atai Beckley (ATAI), and Structure Therapeutics (GPCR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Collegium Pharmaceutical compare to MorphoSys?

MorphoSys (NASDAQ:MOR) and Collegium Pharmaceutical (NASDAQ:COLL) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.

Collegium Pharmaceutical has a net margin of 5.93% compared to MorphoSys' net margin of -226.79%. Collegium Pharmaceutical's return on equity of 91.43% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
Collegium Pharmaceutical	5.93%	91.43%	15.57%

In the previous week, Collegium Pharmaceutical had 4 more articles in the media than MorphoSys. MarketBeat recorded 4 mentions for Collegium Pharmaceutical and 0 mentions for MorphoSys. MorphoSys' average media sentiment score of 0.00 beat Collegium Pharmaceutical's score of -0.26 indicating that MorphoSys is being referred to more favorably in the media.

Company	Overall Sentiment
MorphoSys	Neutral
Collegium Pharmaceutical	Neutral

MorphoSys has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market. Comparatively, Collegium Pharmaceutical has a beta of 0.72, indicating that its stock price is 28% less volatile than the broader market.

Collegium Pharmaceutical has a consensus target price of $48.50, suggesting a potential upside of 113.00%. Given Collegium Pharmaceutical's stronger consensus rating and higher possible upside, analysts clearly believe Collegium Pharmaceutical is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Collegium Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

18.4% of MorphoSys shares are held by institutional investors. 0.1% of MorphoSys shares are held by insiders. Comparatively, 1.9% of Collegium Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Collegium Pharmaceutical has higher revenue and earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A
Collegium Pharmaceutical	$780.57M	0.95	$62.87M	$1.24	18.36

Summary

Collegium Pharmaceutical beats MorphoSys on 12 of the 16 factors compared between the two stocks.

How does Collegium Pharmaceutical compare to MBX Biosciences?

MBX Biosciences (NASDAQ:MBX) and Collegium Pharmaceutical (NASDAQ:COLL) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends.

MBX Biosciences currently has a consensus price target of $77.00, suggesting a potential upside of 22.40%. Collegium Pharmaceutical has a consensus price target of $48.50, suggesting a potential upside of 113.00%. Given Collegium Pharmaceutical's higher possible upside, analysts clearly believe Collegium Pharmaceutical is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77
Collegium Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

MBX Biosciences has a beta of 0.04, indicating that its share price is 96% less volatile than the broader market. Comparatively, Collegium Pharmaceutical has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market.

In the previous week, Collegium Pharmaceutical had 1 more articles in the media than MBX Biosciences. MarketBeat recorded 4 mentions for Collegium Pharmaceutical and 3 mentions for MBX Biosciences. MBX Biosciences' average media sentiment score of 0.45 beat Collegium Pharmaceutical's score of -0.26 indicating that MBX Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MBX Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Collegium Pharmaceutical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Collegium Pharmaceutical has a net margin of 5.93% compared to MBX Biosciences' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 91.43% beat MBX Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-26.02%	-24.94%
Collegium Pharmaceutical	5.93%	91.43%	15.57%

Collegium Pharmaceutical has higher revenue and earnings than MBX Biosciences. MBX Biosciences is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A
Collegium Pharmaceutical	$780.57M	0.95	$62.87M	$1.24	18.36

Summary

Collegium Pharmaceutical beats MBX Biosciences on 10 of the 14 factors compared between the two stocks.

How does Collegium Pharmaceutical compare to Regencell Bioscience?

Collegium Pharmaceutical (NASDAQ:COLL) and Regencell Bioscience (NASDAQ:RGC) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

Collegium Pharmaceutical has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.45, indicating that its share price is 45% more volatile than the broader market.

Collegium Pharmaceutical has a net margin of 5.93% compared to Regencell Bioscience's net margin of 0.00%. Collegium Pharmaceutical's return on equity of 91.43% beat Regencell Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	5.93%	91.43%	15.57%
Regencell Bioscience	N/A	N/A	N/A

0.1% of Regencell Bioscience shares are owned by institutional investors. 1.9% of Collegium Pharmaceutical shares are owned by insiders. Comparatively, 2.0% of Regencell Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Collegium Pharmaceutical presently has a consensus price target of $48.50, indicating a potential upside of 113.00%. Given Collegium Pharmaceutical's stronger consensus rating and higher possible upside, equities analysts clearly believe Collegium Pharmaceutical is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Collegium Pharmaceutical has higher revenue and earnings than Regencell Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$780.57M	0.95	$62.87M	$1.24	18.36
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A

In the previous week, Collegium Pharmaceutical had 4 more articles in the media than Regencell Bioscience. MarketBeat recorded 4 mentions for Collegium Pharmaceutical and 0 mentions for Regencell Bioscience. Regencell Bioscience's average media sentiment score of 0.00 beat Collegium Pharmaceutical's score of -0.26 indicating that Regencell Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
Collegium Pharmaceutical	Neutral
Regencell Bioscience	Neutral

Summary

Collegium Pharmaceutical beats Regencell Bioscience on 9 of the 13 factors compared between the two stocks.

How does Collegium Pharmaceutical compare to Atai Beckley?

Atai Beckley (NASDAQ:ATAI) and Collegium Pharmaceutical (NASDAQ:COLL) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings.

In the previous week, Collegium Pharmaceutical had 4 more articles in the media than Atai Beckley. MarketBeat recorded 4 mentions for Collegium Pharmaceutical and 0 mentions for Atai Beckley. Atai Beckley's average media sentiment score of 0.00 beat Collegium Pharmaceutical's score of -0.26 indicating that Atai Beckley is being referred to more favorably in the media.

Company	Overall Sentiment
Atai Beckley	Neutral
Collegium Pharmaceutical	Neutral

Collegium Pharmaceutical has higher revenue and earnings than Atai Beckley. Atai Beckley is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atai Beckley	$4.09M	666.46	-$660.05M	-$2.18	N/A
Collegium Pharmaceutical	$780.57M	0.95	$62.87M	$1.24	18.36

28.4% of Atai Beckley shares are owned by institutional investors. 19.8% of Atai Beckley shares are owned by company insiders. Comparatively, 1.9% of Collegium Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Atai Beckley presently has a consensus target price of $10.56, suggesting a potential upside of 43.62%. Collegium Pharmaceutical has a consensus target price of $48.50, suggesting a potential upside of 113.00%. Given Collegium Pharmaceutical's stronger consensus rating and higher possible upside, analysts clearly believe Collegium Pharmaceutical is more favorable than Atai Beckley.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atai Beckley	1 Sell rating(s)	14 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.06
Collegium Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Collegium Pharmaceutical has a net margin of 5.93% compared to Atai Beckley's net margin of -14,938.36%. Collegium Pharmaceutical's return on equity of 91.43% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atai Beckley	-14,938.36%	-88.30%	-58.88%
Collegium Pharmaceutical	5.93%	91.43%	15.57%

Atai Beckley has a beta of 1.54, meaning that its stock price is 54% more volatile than the broader market. Comparatively, Collegium Pharmaceutical has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market.

Summary

Collegium Pharmaceutical beats Atai Beckley on 11 of the 17 factors compared between the two stocks.

How does Collegium Pharmaceutical compare to Structure Therapeutics?

Structure Therapeutics (NASDAQ:GPCR) and Collegium Pharmaceutical (NASDAQ:COLL) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Collegium Pharmaceutical has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20M	-$1.00	N/A
Collegium Pharmaceutical	$780.57M	0.95	$62.87M	$1.24	18.36

Structure Therapeutics has a beta of -1.45, indicating that its stock price is 245% less volatile than the broader market. Comparatively, Collegium Pharmaceutical has a beta of 0.72, indicating that its stock price is 28% less volatile than the broader market.

In the previous week, Collegium Pharmaceutical had 1 more articles in the media than Structure Therapeutics. MarketBeat recorded 4 mentions for Collegium Pharmaceutical and 3 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 0.51 beat Collegium Pharmaceutical's score of -0.26 indicating that Structure Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Structure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Collegium Pharmaceutical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Structure Therapeutics presently has a consensus price target of $110.91, indicating a potential upside of 216.88%. Collegium Pharmaceutical has a consensus price target of $48.50, indicating a potential upside of 113.00%. Given Structure Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Structure Therapeutics is more favorable than Collegium Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.82
Collegium Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Collegium Pharmaceutical has a net margin of 5.93% compared to Structure Therapeutics' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 91.43% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-25.56%	-24.31%
Collegium Pharmaceutical	5.93%	91.43%	15.57%

91.8% of Structure Therapeutics shares are owned by institutional investors. 5.5% of Structure Therapeutics shares are owned by company insiders. Comparatively, 1.9% of Collegium Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Collegium Pharmaceutical beats Structure Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Collegium Pharmaceutical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COLL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COLL vs. The Competition

Export

Metric	Collegium Pharmaceutical	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$728.59M	$12.48B	$7.25B	$13.14B
Dividend Yield	N/A	2.63%	2.57%	12.30%
P/E Ratio	18.36	797.25	275.79	25.40
Price / Sales	0.95	950.97	695.58	114.44
Price / Cash	1.47	88.44	77.42	51.66
Price / Book	2.39	10.53	10.46	6.33
Net Income	$62.87M	$2.82B	$3.49B	$358.33M
7 Day Performance	0.09%	1.69%	0.59%	1.12%
1 Month Performance	-20.77%	0.83%	-2.01%	-2.67%
1 Year Performance	-36.31%	3.90%	18.09%	6.01%

Collegium Pharmaceutical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
COLL Collegium Pharmaceutical	3.0069 of 5 stars	$22.77 +1.7%	$48.50 +113.0%	-37.0%	$728.59M	$780.57M	18.36	423	High Trading Volume
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730
MBX MBX Biosciences	2.6121 of 5 stars	$59.49 +0.8%	$77.00 +29.4%	+524.7%	$2.84B	N/A	N/A	63
RGC Regencell Bioscience	0.1475 of 5 stars	$5.74 +1.8%	N/A	-61.8%	$2.79B	N/A	N/A	10
ATAI Atai Beckley	2.3308 of 5 stars	$7.35 flat	$10.56 +43.6%	N/A	$2.73B	$4.09M	N/A	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:COLL) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Collegium Pharmaceutical (COLL) Competitors

COLL vs. MOR, MBX, RGC, ATAI, and GPCR

How does Collegium Pharmaceutical compare to MorphoSys?

Summary

How does Collegium Pharmaceutical compare to MBX Biosciences?

Summary

How does Collegium Pharmaceutical compare to Regencell Bioscience?

Summary

How does Collegium Pharmaceutical compare to Atai Beckley?

Summary

How does Collegium Pharmaceutical compare to Structure Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COLL vs. The Competition

Collegium Pharmaceutical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Collegium Pharmaceutical (COLL) Competitors

COLL vs. MOR, MBX, RGC, ATAI, and GPCR

How does Collegium Pharmaceutical compare to MorphoSys?

Is MOR or COLL more profitable?

Does the media refer more to MOR or COLL?

Which has more risk and volatility, MOR or COLL?

Do analysts prefer MOR or COLL?

Do institutionals & insiders hold more shares of MOR or COLL?

Which has preferable earnings and valuation, MOR or COLL?

Summary

How does Collegium Pharmaceutical compare to MBX Biosciences?

Do analysts rate MBX or COLL?

Which has more risk and volatility, MBX or COLL?

Does the media refer more to MBX or COLL?

Is MBX or COLL more profitable?

Which has preferable valuation and earnings, MBX or COLL?

Summary

How does Collegium Pharmaceutical compare to Regencell Bioscience?

Which has more risk & volatility, COLL or RGC?

Is COLL or RGC more profitable?

Do institutionals and insiders believe in COLL or RGC?

Do analysts prefer COLL or RGC?

Which has preferable valuation & earnings, COLL or RGC?

Does the media prefer COLL or RGC?

Summary

How does Collegium Pharmaceutical compare to Atai Beckley?

Does the media prefer ATAI or COLL?

Which has higher earnings & valuation, ATAI or COLL?

Do institutionals & insiders have more ownership in ATAI or COLL?

Do analysts prefer ATAI or COLL?

Is ATAI or COLL more profitable?

Which has more risk and volatility, ATAI or COLL?

Summary

How does Collegium Pharmaceutical compare to Structure Therapeutics?

Which has stronger valuation & earnings, GPCR or COLL?

Which has more risk and volatility, GPCR or COLL?

Does the media prefer GPCR or COLL?

Do analysts recommend GPCR or COLL?

Is GPCR or COLL more profitable?

Do insiders & institutionals have more ownership in GPCR or COLL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COLL vs. The Competition

Collegium Pharmaceutical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools